Mucin sialylation drives epithelial cell senescence and severe asthma
Mucin sialylation drives epithelial cell senescence and severe asthma
批准号:
10206266
负责人:
Richard Charles Boucher
金额:
$69.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2024-06-30
关键词:
AgonistAsthmaBiologicalBiological MarkersCCND1 geneCarbohydratesCell AgingCell CommunicationCell CountCell Culture TechniquesCell Differentiation processCell surfaceCellsChronicDataDiseaseERBB2 geneEpidermal Growth Factor ReceptorEpithelialEpithelial Cell ProliferationEpithelial CellsEvolutionFamilyFamily memberFunctional disorderGalactosidesGene ExpressionGenesGlutathioneGlutathione DisulfideGoblet CellsHumanHuman BiologyHyperplasiaIn VitroInflammationInterleukin-13LinkLungMeasuresMetabolicMetabolic dysfunctionMetabolic stressMetabolismMitochondriaMucinsMusOxidative StressPathway interactionsPhenotypePost-Translational Protein ProcessingProcessProteinsProto-Oncogene Proteins c-aktPublishingPyroglyphidaeReportingRoleSeveritiesSeverity of illnessSialyltransferasesSputumStimulusTNF geneTestingTimeTissuesTransgenic MiceUp-Regulationairway epitheliumasthma exacerbationasthmaticasthmatic airwayasthmatic patientcell typedriving forceepithelial woundextracellularglycosylationimprovedin vivomTOR inhibitionmouse modelnew therapeutic targetnoveloxidationparticleprotein expressionreceptorsenescencesialylationwound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This application explores the paradigm shifting hypothesis that post-translational modification (sialylation) of a
cell surface (tethered) mucin, MUC4, drives terminal differentiation and senescence of airway epithelial cells
(AECs) through inhibition of epidermal growth factor receptor (EGFR) family pathways, worsening epithelial
wound repair and asthma severity. Our proposed studies will be the first to specifically test tethered mucins and
their post-translational N-glycosylation/sialylation for a role in AEC terminal differentiation and senescence. Our
published data (Zhou et al) demonstrate that sialylation of the tethered mucin, MUC4β, i.e., MUC4α βSA, controls
goblet cell terminal differentiation as a function of β-galactoside α2,6-sialyltransferase-1 (ST6GAL1) activity.
Both ST6GAL1 and MUC4β critically lower AEC proliferative capacity, with additional published data (Inoue et
al) linking diminished AEC proliferation to abnormal wound repair in vitro. Reduced AEC proliferative capacity
may reflect reduced activation of the EGFR family member, ErbB2, a known receptor for MUC4β. New data
confirm that elevations in MUC4 and ST6GAL1 are present in severe exacerbation-prone asthma and in house
dust mite challenged mice. Elevations in both biologically associate with low intracellular glutathione (GSH) to
oxidized glutathione (GSSG) ratios (oxidative stress) and lower mitochondrial and senescence gene expression.
Parallel in vitro AEC data show T2 inflammation/IL-13 alters intracellular metabolism and mitochondria,
decreases GSH/GSSG, and further decreases wound repair. Yet, the overall impact of MUC4β and/or its
sialylation to epithelial cell phenotypes, cell senescence, and the mechanisms by which these changes contribute
to severe asthma are unclear. The studies proposed here will comprehensively evaluate the intersection of
mucins, mucin sialylation, and senescence pathway(s), while robustly testing their functional importance using
primary human AEC cell cultures and transgenic mouse models. The three proposed aims will: 1) elucidate the
mechanistic and functional impact of MUC4β and MUC4βSA on AEC terminal differentiation, senescence and
wound repair in vitro, 2) test the functional impact of Muc4βSA-AEC interactions on mucin secretion, goblet cell
hyperplasia/terminal differentiation, senescence, and wound repair in an asthma mouse model and 3) define the
relationship of MUC4βSA to senescence and AEC phenotypes in human asthma patients. These concurrent aims
will iteratively develop data that link mucins, their sialylation and fundamental senescence-related epithelial
processes to identify highly novel targets for treatment of severe asthma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UNC Research Training Program in Respiratory Diseases and Critical Care
-
批准号:10714527
-
项目类别:
-
资助金额:$52.69万
-
财政年份:2023
-
负责人:Richard Charles Boucher
-
依托单位:
The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)
-
批准号:10393987
-
项目类别:
-
资助金额:$74.85万
-
财政年份:2022
-
负责人:Richard Charles Boucher
-
依托单位:
Project 2: Why are mucins so gigantic and is it safe/effective to sever them therapeutically?
-
批准号:10684198
-
项目类别:
-
资助金额:$55.3万
-
财政年份:2022
-
负责人:Richard Charles Boucher
-
依托单位:
Core A: Administrative/Biostatistics Core
-
批准号:10684186
-
项目类别:
-
资助金额:$19.1万
-
财政年份:2022
-
负责人:Richard Charles Boucher
-
依托单位:
The molecular and cellular mechanisms of the STAT3 mutation-mediated pulmonary disorder in Autosomal Dominant Hyper IgE Syndrome (AD-HIES)
-
批准号:10584596
-
项目类别:
-
资助金额:$73.42万
-
财政年份:2022
-
负责人:Richard Charles Boucher
-
依托单位:
Diversity Supplement for PhD student Shamarie King under Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease
-
批准号:10852415
-
项目类别:
-
资助金额:$10.26万
-
财政年份:2022
-
负责人:Richard Charles Boucher
-
依托单位:
Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease
-
批准号:10684185
-
项目类别:
-
资助金额:$275.76万
-
财政年份:2022
-
负责人:Richard Charles Boucher
-
依托单位:
Mucin sialylation drives epithelial cell senescence and severe asthma
-
批准号:10664889
-
项目类别:
-
资助金额:$69.55万
-
财政年份:2020
-
负责人:Richard Charles Boucher
-
依托单位:
Mucin sialylation drives epithelial cell senescence and severe asthma
-
批准号:10026633
-
项目类别:
-
资助金额:$74.68万
-
财政年份:2020
-
负责人:Richard Charles Boucher
-
依托单位:
Mucin sialylation drives epithelial cell senescence and severe asthma
-
批准号:10434719
-
项目类别:
-
资助金额:$69.6万
-
财政年份:2020
-
负责人:Richard Charles Boucher
-
依托单位:
Development of Novel Mycolytic Therapies for Lung Disease
-
批准号:10001578
-
项目类别:
-
资助金额:$217.4万
-
财政年份:2017
-
负责人:Richard Charles Boucher
-
依托单位:
Project 2: PK/PD requirements for mucolytic therapeutic agents in vitro and in vivo
-
批准号:10001600
-
项目类别:
-
资助金额:$47.8万
-
财政年份:2017
-
负责人:Richard Charles Boucher
-
依托单位:
Core A: Program Management and Biostatistics Core
-
批准号:10001594
-
项目类别:
-
资助金额:$21.34万
-
财政年份:2017
-
负责人:Richard Charles Boucher
-
依托单位:
Core A: Program Management and Biostatistics Core
-
批准号:9356814
-
项目类别:
-
资助金额:$22.14万
-
财政年份:2017
-
负责人:Richard Charles Boucher
-
依托单位:
Synthesis of Effective and Safe Mucolytics for Pulmonary Disease
-
批准号:9144907
-
项目类别:
-
资助金额:$152.2万
-
财政年份:2014
-
负责人:Richard Charles Boucher
-
依托单位:
Synthesis of Effective and Safe Mucolytics for Pulmonary Disease
-
批准号:8754410
-
项目类别:
-
资助金额:$145.95万
-
财政年份:2014
-
负责人:Richard Charles Boucher
-
依托单位:
Novel Therapies for Muco-Obstructive Lung Diseases
-
批准号:8490422
-
项目类别:
-
资助金额:$242.37万
-
财政年份:2012
-
负责人:Richard Charles Boucher
-
依托单位:
Pulmonary Surface Liquid Homeostasis
-
批准号:8467747
-
项目类别:
-
资助金额:$205.02万
-
财政年份:2012
-
负责人:Richard Charles Boucher
-
依托单位:
Pulmonary Surface Liquid Homeostasis
-
批准号:8914311
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2012
-
负责人:Richard Charles Boucher
-
依托单位:
Pulmonary Surface Liquid Homeostasis
-
批准号:8658455
-
项目类别:
-
资助金额:$211.05万
-
财政年份:2012
-
负责人:Richard Charles Boucher
-
依托单位:
海外基金